Patents
Literature
53results about How to "Thwart these maladies" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
InactiveUS6890763B2Maximize diversityThwart these maladiesAnalysis using chemical indicatorsPeptide/protein ingredientsDiseaseBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons
InactiveUS20060024755A1Maximize diversityThwart these maladiesBiological testingBiopolymerSpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer.
Owner:JACKOWSKI GEORGE +5
IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Protein biopolymer markers predictive of insulin resistance
InactiveUS20060211138A1Thwart these maladiesApolipeptidesMaterial analysis by electric/magnetic meansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:JACKOWSKI GEORGE +1
Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
InactiveUS20060211146A1Rapidly and accurately diagnosingConvenient treatmentProtease inhibitorsAnimals/human peptidesMass spectrometrySpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:JACKOWSKI GEORGE +1
Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
InactiveUS7314717B2Maximize diversityThwart these maladiesAnalysis using chemical indicatorsPeptide/protein ingredientsDiseaseBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Protein biopolymer markers predictive of insulin resistance
InactiveUS20060205091A1Thwart these maladiesApolipeptidesImmunoglobulins against animals/humansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:JACKOWSKI GEORGE +1
Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
InactiveUS7132244B2Thwart these maladiesPeptide/protein ingredientsPeptide preparation methodsDisease riskBetaine
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Protein biopolymer markers indicative of insulin resistance
InactiveUS7135297B2Thwart these maladiesPeptide/protein ingredientsImmunoglobulins against animals/humansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against disease.
Owner:NANOGEN INC
Protein biopolymer markers predictive of insulin resistance
InactiveUS20060211140A1Thwart these maladiesApolipeptidesMaterial analysis by electric/magnetic meansDisease riskBiopolymer
Owner:JACKOWSKI GEORGE +1
Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
InactiveUS20060211145A1Rapidly and accurately diagnosingConvenient treatmentPeptide preparation methodsDepsipeptidesDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Protein biopolymer markers indicative of insulin resistance
InactiveUS20060194339A1Thwart these maladiesPeptide/protein ingredientsImmunoglobulins against animals/humansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Protein biopolymer markers predictive of insulin resistance
InactiveUS7052849B2Rapidly and accurately diagnosingConvenient treatmentApolipeptidesImmunoglobulins against animals/humansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Protein biopolymer markers indicative of alzheimer's disease
InactiveUS7074576B2Thwart these maladiesNervous disorderPeptide/protein ingredientsDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Complement C3 precursor biopolymer markers predictive of type II diabetes
InactiveUS7097989B2Thwart these maladiesPeptide/protein ingredientsMaterial analysis by electric/magnetic meansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
InactiveUS7294688B2Maximize diversityThwart these maladiesPeptide/protein ingredientsImmunoglobulinsDiseaseBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
InactiveUS20060211048A1Maximize diversityThwart these maladiesBiological testingImmunoassaysBiopolymerSpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer.
Owner:JACKOWSKI GEORGE +4
Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
InactiveUS20060134699A1Thwart these maladiesSerum immunoglobulinsImmunoglobulins against animals/humansBiopolymerTrypsin inhibitor
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:JACKOWSKI GEORGE +1
Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
InactiveUS7049397B2Maximize diversityThwart these maladiesPeptide/protein ingredientsImmunoglobulinsBiopolymerMass spectrometry
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer.
Owner:NANOGEN INC
Complement c3 precursor biopolymer markers predictive of type ii diabetes
InactiveUS20060160232A1Rapidly and accurately diagnosingConvenient treatmentPeptide/protein ingredientsMaterial analysis by electric/magnetic meansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Fibronectin biopolymer marker indicative of insulin resistance
InactiveUS7094549B2Thwart these maladiesImmunoglobulins against blood coagulation factorsPeptide/protein ingredientsDisease riskMedicine
Owner:NANOGEN INC +1
Ig heavy chain, ig kappa, ig lambda biopolymer markers predictive of alzheimers disease
InactiveUS20060160233A1Rapidly and accurately diagnosingConvenient treatmentCompound screeningApoptosis detectionDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Fibronectin precursor biopolymer markers indicative of alzheimer's disease
InactiveUS7179605B2Thwart these maladiesCompound screeningNervous disorderBiopolymerMass spectrometry
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
InactiveUS6998243B2Maximize diversityThwart these maladiesPeptide/protein ingredientsPeptide sourcesBiopolymerMass spectrometry
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Glycoprotein and apolipoprotein biopolymer markers predictive of Alzheimers disease
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
Owner:NANOGEN INC
Method and kit for diagnosing myocardial infarction
InactiveUS7125726B2Maximize diversityThwart these maladiesPeptide/protein ingredientsPeptide sourcesBiopolymerSpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:ARTEMIS PROTEOMICS
Protein biopolymer markers predictive of type II diabetes
InactiveUS7125678B2Thwart these maladiesPeptide/protein ingredientsMaterial analysis by electric/magnetic meansDisease riskBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
HP biopolymer markers predictive of insulin resistance
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or the absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
Owner:NANOGEN INC
Biopolymer marker indicative of disease state having a molecular weight of 1525 daltons
InactiveUS20060024671A1Maximize diversityThwart these maladiesMicrobiological testing/measurementBiological testingBiopolymerSpectroscopy
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer.
Owner:ARTEMIS PROTEOMICS
Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons
InactiveUS7087435B2Maximize diversityThwart these maladiesPeptide/protein ingredientsPeptide sourcesDiseaseBiopolymer
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer.
Owner:NANOGEN INC
Popular searches
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com